Table 1 Patient demographics and clinical characteristics (intention-to-treat population)

From: Erlotinib versus gemcitabine plus cisplatin as neoadjuvant treatment of stage IIIA-N2 EGFR-mutant non-small-cell lung cancer: final overall survival analysis of the EMERGING-CTONG 1103 randomised phase II trial

 

Erlotinib group (n = 37)

GC group (n = 35)

Sex

Male

11 (29.7)

8 (22.9)

Female

26 (70.3)

27 (77.1)

Ethnic group

Han

36 (97.3)

33 (94.3)

Others

1 (2.7)

2 (5.7)

Median age, years (range)

59 (32–73)

58 (33–76)

Smoking status

Never smokers

29 (78.4)

31 (88.6)

Current smokers

6 (16.2)

2 (5.7)

Former smokers

2 (5.4)

2 (5.7)

ECOG PS score

0

13 (35.1)

14 (40.0)

1

24 (64.9)

21 (60.0)

Pathological type

Adenocarcinoma

32 (86.5)

33 (94.3)

Non-adenocarcinoma

5 (13.5)

2 (5.7)

Preoperative staging

Mediastinoscopy

12 (32.4)

9 (25.7)

Bronchial ultrasound

12 (32.4)

16 (45.7)

PET/CT

13 (35.2)

10 (28.6)

T stage

T1

12 (32.4)

5 (14.3)

T2

16 (43.3)

20 (57.1)

T3

7 (18.9)

10 (28.6)

T4

1 (2.7)

0 (0.0)

Tx

1 (2.7)

0 (0.0)

N2 status

Single-station N2

17 (45.9)

19 (54.3)

Multi-station N2

20 (54.1)

16 (45.7)

EGFR-activating mutations

Exon 19 mutation

16 (43.2)

18 (51.4)

Exon 21 mutation

21 (56.8)

17 (48.6)

  1. Data are n (%) unless otherwise stated
  2. CT computed tomography, ECOG PS Eastern Cooperative Oncology Group performance status, EGFR epidermal growth factor receptor, GC gemcitabine plus cisplatin, PET positron emission tomography, x the primary tumour could not be evaluated
Back to article page